BeiGene Ltd. - Asset Resilience Ratio
BeiGene Ltd. (49B) has an Asset Resilience Ratio of 0.00% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 49B strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how BeiGene Ltd.'s Asset Resilience Ratio has changed over time. See net asset quality index of BeiGene Ltd. to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down BeiGene Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 49B stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: BeiGene Ltd. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
BeiGene Ltd. Industry Peers by Asset Resilience Ratio
Compare BeiGene Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for BeiGene Ltd. (2016–2023)
The table below shows the annual Asset Resilience Ratio data for BeiGene Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.04% | €2.60 Million ≈ $3.04 Million |
€5.81 Billion ≈ $6.79 Billion |
-10.38pp |
| 2022-12-31 | 10.43% | €665.25 Million ≈ $777.75 Million |
€6.38 Billion ≈ $7.46 Billion |
-15.50pp |
| 2021-12-31 | 25.93% | €2.24 Billion ≈ $2.62 Billion |
€8.65 Billion ≈ $10.11 Billion |
-32.43pp |
| 2020-12-31 | 58.36% | €3.27 Billion ≈ $3.82 Billion |
€5.60 Billion ≈ $6.55 Billion |
+35.74pp |
| 2019-12-31 | 22.62% | €364.73 Million ≈ $426.41 Million |
€1.61 Billion ≈ $1.88 Billion |
-24.87pp |
| 2018-12-31 | 47.50% | €1.07 Billion ≈ $1.25 Billion |
€2.25 Billion ≈ $2.63 Billion |
-9.64pp |
| 2017-12-31 | 57.14% | €597.91 Million ≈ $699.02 Million |
€1.05 Billion ≈ $1.22 Billion |
-12.02pp |
| 2016-12-31 | 69.16% | €280.66 Million ≈ $328.12 Million |
€405.81 Million ≈ $474.44 Million |
-- |
About BeiGene Ltd.
BeOne Medicines Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the trea… Read more